Hyponatremia Clinical Trial
Official title:
A RCT to Evaluate the Effect of Normal Saline in 5% Dextrose at Maintenance Rate, N/5 Saline in 5% Dextrose at 2/3 Maintenance Rate and N/5 Saline in 5% Dextrose at Maintenance Rate on Incidence of Hyponatremia in Hospitalized Children.
Hyponatraemia arises in between 20% and 45% of sick hospitalized children. An important
reason for this high incidence could be use of hypotonic fluids in sick children for
maintenance fluid therapy. There are no randomized controlled trials to evaluate the effect
of various types of intravenous fluids on the incidence of hyponatremia in sick hospitalized
children.
Hypothesis: Use of normal saline in 5% dextrose or reduced (2/3) volume of N/5 saline in 5%
dextrose reduces incidence of hyponatremia (serum sodium 130 mmol/L) by two-thirds when
compared to N/5 saline in 5% dextrose at standard maintenance rate in hospitalized children
receiving intravenous maintenance fluids.
Hyponatraemia arises in between 20% and 45% of sick hospitalized children. An important
reason for this high incidence could be use of hypotonic fluids in sick children for
maintenance fluid therapy. There are no randomized controlled trials to evaluate the effect
of various types of intravenous fluids on the incidence of hyponatremia in sick hospitalized
children. We therefore plan to conduct a randomized controlled trial to evaluate the effect
of normal saline in 5% dextrose at standard maintenance rate, reduced volume (2/3
maintenance rate) of N/5 saline in 5% dextrose and N/5 saline in 5% dextrose at standard
maintenance rate on the incidence of hyponatremia in hospitalized children, aged 3 months-
12 years. To determine serial plasma vasopressin levels in hospitalized children at
baseline, 24 hours and 48 hours of intravenous fluid therapy and compare the values in the
three fluid regimens.
Study design: Randomized controlled trial. Hospitalized children who fulfill inclusion
criteria and not having any of the exclusion criteria will be considered for the enrolment
after written informed consent. Venous blood samples will be taken at enrollment for
estimation of serum sodium, potassium, chloride, bicarbonate, blood gas, blood sugar, blood
urea, serum creatinine, and plasma osmolality. A sample for estimation of plasma vasopressin
will be collected at baseline. After randomization into three groups, one group of children
will receive N/5 saline in 5% dextrose at standard maintenance rate (100 ml/kg for the first
10 kg of body weight, 50 ml/kg for the next 10 kg, and 20 ml/kg for body weight exceeding 20
kg).The second group of children will receive N/5 saline in 5% dextrose at 2/3 maintenance
rate. The third group will receive dextrose normal saline at standard maintenance rate.
Serum Na+, K+ and urine Na+, K+ will be estimated every 12 hourly till the patient is on
intravenous fluid therapy and 12 hrs after stopping exclusive intravenous maintenance
fluids. Serum and urine osmolality will be estimated every 24 hrs by an osmometer. Plasma
vasopressin will be estimated in children in the 3 groups at 24, and 48 hours of intravenous
fluid therapy.
Children will be weighed every 24 hours. The fluid balance, sodium balance, free water
clearance will be calculated in a subset of children.
The study measurements will be carried out only till the time the child is on exclusive
intravenous maintenance fluid therapy or 72 hrs of starting the intravenous fluid therapy.
The decision to decrease/ stop intravenous fluid therapy will be left to the treating unit.
The primary outcome measure will be incidence of hyponatremia (defined as serum Na+ less
than 130 mmol/L).
The secondary outcomes studied will be Plasma vasopressin levels at 24 hr and 48 hours and
incidence of hypernatremia.
Sample size: Based on literature review, the incidence of hyponatremia with standard
intravenous fluid therapy is approximately 30%. Sample of 72 patients will be needed in each
group to demonstrate the decrease in incidence of hyponatremia to 10%, with a beta of 0.2
(Power 80%) and alpha error of 0.05.
Analysis: The data will be analyzed using STATA software. The outcomes (primary and
secondary) in the 3 groups will be compared. For continuous variables, t test or Wilcoxon
rank-sum test will be used to determine statistical significance. For categorical variables,
chi square test will be used.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06037928 -
Plasma Sodium and Sodium Administration in the ICU
|
||
Recruiting |
NCT04561531 -
Efficacy and Safety of Bolus Comparing With Continuous Drip of 3% NaCl in Patients With Severe Symptomatic Hyponatremia.
|
N/A | |
Terminated |
NCT02012959 -
Study of the Safety and Effectiveness of SAMSCA® (Tolvaptan) in Children and Adolescents With Euvolemic or Hypervolemic Hyponatremia
|
Phase 3 | |
Recruiting |
NCT02936167 -
Comparison of Ringer Lactate and Isotonic Acetate Solution as Perioperative Maintenance Fluid for Children
|
N/A | |
Terminated |
NCT03703713 -
Colloid Osmotic Pressure and Osmolality in Hyponatremia
|
||
Completed |
NCT02926989 -
Intravenous Fluids in Hospitalised Children
|
Phase 4 | |
Terminated |
NCT02959411 -
Tolvaptan for Advanced or Refractory Heart Failure
|
Phase 4 | |
Completed |
NCT02573077 -
An Observational Study Measuring Outcomes in Cancer Patients Treated for Moderate to Severe Hyponatremia in Italy
|
||
Withdrawn |
NCT02667977 -
Reexamining Hypotonic Intravenous Fluid Use
|
N/A | |
Terminated |
NCT01708811 -
Hyponatremia and Myometrium Contractility. An Invitro Study
|
N/A | |
Completed |
NCT01456533 -
Copeptin in the Differential Diagnosis of Dysnatremia in Hospitalized Patients
|
N/A | |
Withdrawn |
NCT01326429 -
Frequency and Origin of Dysnatremias in the Emergency Department
|
N/A | |
Terminated |
NCT01227512 -
Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia
|
Phase 3 | |
Recruiting |
NCT06013800 -
Hyponatremia Volume Status Analysis by Point-of-care Ultrasound
|
||
Terminated |
NCT04020926 -
Impact of Hyponatremia on Muscle Strength, Gait and Cognitive Function
|
||
Completed |
NCT02545101 -
An Observational Study on Real-world Use and Outcomes of Patients Treated With Tolvaptan for Hyponatraemia Due to SIADH
|
N/A | |
Withdrawn |
NCT02442674 -
A Trial of Tolvaptan in Children and Adolescent Subjects With Euvolemic and Hypervolemic Hyponatremia
|
Phase 3 | |
Terminated |
NCT02215148 -
Pharmacokinetics and Clinical Response of Tolvaptan in Neurocritical Care Patients
|
N/A | |
Recruiting |
NCT01748331 -
The Effect of Fluid Restriction in Congestive Heart Failure Complicated With Hyponatremia
|
N/A | |
Not yet recruiting |
NCT01716611 -
Tolvaptan for Hyponatremia in Cirrhotic Patients With Ascites
|
Phase 4 |